Electroencephalography (EEG) is the science of recording the spontaneous rhythmic electrical activity of a living brain through electrodes on the scalp. Brain rhythms have origins similar to the electrical activity of the heart. The rhythmic activity varies in frequency and amplitude with age, attention, sleep, and chemical concentrations of oxygen, carbon dioxide, glucose, ammonia, and hormones. Chemicals that affect brain functions change brain rhythms in systematic and identifiable ways. As new psychoactive drugs were discovered that changed behavior, the basis for the science of psychopharmacology, the accompanying changes in the rhythms were found to be drug class specific. The measurement of the changes in rhythms became the basis for the science of pharmaco-EEG.
Definitions of the changes in EEG rhythms were developed that identified and classified psychoactive drugs, monitored the depth of anesthesia, and evaluated the efficacy of the seizures induced in convulsive therapy (electroshock).
History
The first recordings of electrical activity from the brain were reported from exposed animal brain tissues in the 1870s. In 1929 Hans Berger, a German psychiatrist, reported continuous electrical rhythms from the intact human head using electrodes on the scalp. The continuous electrical activity varied in frequencies and amplitude with drowsiness and sleep, and with mental problem solving. Episodic runs and bursts of high voltage slow frequencies were recorded in patients with epilepsy.
In his third report in 1931 Berger recorded changes in the rhythms with cocaine, morphine, scopolamine, and chloroform. Each chemical elicited different frequency and amplitude patterns and different behaviors.
The first clinical applications were in identifying the sudden bursts of high voltage slow frequencies during seizures, both spontaneous and induced by the chemical pentylenetetrazol (Metrazol), by electricity in electroshock, and in the coma induced by insulin. When reserpine was studied in 1953, chlorpromazine in 1954, and imipramine in 1957, individual rhythmic patterns were described.
The EEG patterns of new psychoactive drugs predicted their clinical activity. By the 1960s, EEG analysis of psychoactive drugs was a feature of the NIMH Early Clinical Drug Evaluation (ECDEU) program that evaluated and identified new psychiatric treatments. Proposed psychoactive drugs developed in chemical laboratories were first tested in animals and then tested in man. The changes in the EEG became the basis for a classification of new drugs.
Assessment methods in human volunteers were developed that recorded the changes in the resting subject at different dosages, both on acute single administrations and repeated daily dosing. The observed changes were compared to those for known drugs and predicted their behavioral effects. When no systematic changes were recorded, the agents were considered not to have a clinical use.
Dosing schedules were optimized. In patients who failed to respond to prescribed treatments, those who were considered "pharmacotherapy resistant," EEG studies showed that the chemicals did not elicit identifiable brain changes.
In pre-clinical animal trials EEG recordings were associated the changes with vigilance and motor measures, concluding that the EEG patterns were "dissociated," that is, bearing little relationship to the changes in behavior. In human trials, however, when the EEG measures could be related to vigilance, mood, memory, and psychological tests, a theory of "association of EEG and behavior" developed and sustained pharmaco-EEG studies of new drugs.
The technology was applied in anesthesia, identifying the efficacy of individual seizures in convulsive therapy, in studies of sleep patterns, and the relation of evoked potentials to speech and psychological tests.
Social changes in attitudes to the ethics of testing drugs and treatments in patients, prisoners, children, and volunteers inhibited the continued development of the science and its abandonment.
Methodology
Polypharmacy and the widespread use of active psychiatric drugs made the study of individual compounds in psychiatric patients difficult. The science then successfully focused on alert male volunteers (since the EEG varied with menstrual cycles in women).[citation needed]
Vigilance. The scalp recorded EEG is sensitive to changes in vigilance. Different methods developed to sustain a monitored level of alertness using hand held buzzers that sounded off when the subject relaxed and dozed.
Volunteer Baseline and Placebo training. As the EEG is sensitive to anxiety, an initial training session became standard procedure. The baseline recording identified subjects whose records were unique.
EEG recording. Different electrode placements were tested. Commonly the recordings were made using the frontal-occipital or the bifrontal leads. Standard EEG amplifiers were used.
Quantification and analyses. In the beginning the EEG recordings were made on paper and changes measured visually, scored by ruler and calipers. By the 1960s, electronic analyzers of 10 second epochs measured changes in "power." Digital computer methods using period analysis, power spectral density, and amplitude analyses followed.
The quantitative changes in mean frequency, mean amplitudes, percent time delta (1–3Hz), theta (3.5 - 7.5Hz), alpha (8-12.5Hz), beta1 (13–21Hz), and beta2 (>21Hz), and the presence of bursts in 10-second epochs were commonly used to identify patterns.
Predictive patterns. The measures related the EEG changes to the common classes of psychoactive drugs—antidepressant, anxiolytic, antipsychotic, hallucinogen, deliriant, euphoriant, and mood stabilizer being the most frequent. For a time, the pharmaco-EEG profiles of different classes of drugs were actively used to identify active psychotropic agents.
Applications
Psychopharmacology. Pharmaco-EEG studies were economically useful in clinically classifying new agents, dosage ranges and durations of effects, and separating active from inactive substances. The list of successful applications is extensive; some specific examples are the identification of mianserin (GB-94) and doxepin as antidepressants of the imipramine class; of the inactivity of flutroline as a proposed antipsychotic in man despite activity in dogs; and of equivalent EEG activity of the laevo and dextro enantiomers of 6-azamianserin (mirtazapine) despite differences in preclinical trials.
Studies of different cannabis formulations (hashish, marijuana, tetrahydrocannabinol-∆-9 extract each showed the same patterns in EEG, cardiovascular, and clinical profiles. Tolerance development was marked in acute administration of cannabis in chronic hashish users.
In testing narcotic antagonists (naloxone, cyclazocine) and opioid substitutes (methadone, levomethadyl) in the treatment of opioid dependence, the quantitative EEG experiments showed the efficiency of antagonistic and replacement activity of different dosing schedules. Dose finding trials of naloxone showed no specific CNS effect when administered alone but very effective antagonistic action in opioid dose and overdose.
Convulsive therapy. The grandmal seizure is the central event in electroshock (electroconvulsive therapy, ECT) and insulin coma. It was introduced in 1934 and by the 1940s EEG recordings during the treatment showed the classic sequence of epileptic seizure events recognized as the "grand mal seizure." In the 1950s, recordings of interseizure records, on days after an induced seizure, showed progressive slowing of mean frequencies and increased amplitudes during the treatment course. These changes were necessary accompaniments of effective courses of treatment—patients without progressive slowing failed to recover.
In the early 1980s, commercial ECT devices were equipped with a 2-channel EEG recorder that measured the EEG characteristics and duration. The quality of the EEG record became the standard for an "effective" treatment. The same quantitative measures used in psychopharmacology were established in clinical ECT.
Anesthesia. Specialized equipment to monitor ongoing identification of anesthesia stages are common in modern surgical units.
Related Research Articles
Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, and behavior. It is distinguished from neuropsychopharmacology, which emphasizes the correlation between drug-induced changes in the functioning of cells in the nervous system and changes in consciousness and behavior.
A psychiatric or psychotropic medication is a psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system. Thus, these medications are used to treat mental illnesses. Usually prescribed in psychiatric settings, these medications are typically made of synthetic chemical compounds. Since the mid-20th century, such medications have been leading treatments for a broad range of mental disorders and have decreased the need for long-term hospitalization, therefore lowering the cost of mental health care. The recidivism or rehospitalization of the mentally ill is at a high rate in many countries and the reasons for the relapses are under research.
Sertraline, sold under the brand name Zoloft among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive–compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder. Sertraline is taken by mouth.
Maprotiline, sold under the brand name Ludiomil among others, is a tetracyclic antidepressant (TeCA) that is used in the treatment of depression. It may alternatively be classified as a tricyclic antidepressant (TCA), specifically a secondary amine. In terms of its chemistry and pharmacology, maprotiline is closely related to other secondary amine TCAs like nortriptyline and protriptyline, and has similar effects to them.
Serotonin–norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant drugs that treat major depressive disorder (MDD), anxiety disorders, obsessive–compulsive disorder (OCD), social phobia, attention-deficit hyperactivity disorder (ADHD), chronic neuropathic pain, fibromyalgia syndrome (FMS), and menopausal symptoms. SNRIs are monoamine reuptake inhibitors; specifically, they inhibit the reuptake of serotonin and norepinephrine. These neurotransmitters are thought to play an important role in mood regulation. SNRIs can be contrasted with the more widely used selective serotonin reuptake inhibitors (SSRIs), which act upon serotonin only.
A paradoxical reaction or paradoxical effect is an effect of a chemical substance, mostly a medical drug, opposite to the effect which would normally be expected. An example of a paradoxical reaction is pain caused by a pain relief medication.
Noradrenergic and specific serotonergic antidepressants (NaSSAs) are a class of psychiatric drugs used primarily as antidepressants. They act by antagonizing the α2-adrenergic receptor and certain serotonin receptors such as 5-HT2A and 5-HT2C, but also 5-HT3, 5-HT6, and/or 5-HT7 in some cases. By blocking α2-adrenergic autoreceptors and heteroreceptors, NaSSAs enhance adrenergic and serotonergic neurotransmission in the brain involved in mood regulation, notably 5-HT1A-mediated transmission. In addition, due to their blockade of certain serotonin receptors, serotonergic neurotransmission is not facilitated in unwanted areas, which prevents the incidence of many side effects often associated with selective serotonin reuptake inhibitor (SSRI) antidepressants; hence, in part, the "specific serotonergic" label of NaSSAs.
Viloxazine is a morpholine derivative and is a selective norepinephrine reuptake inhibitor (NRI). It was used as an antidepressant in some European countries, and produced a stimulant effect that is similar to the amphetamines, except without any signs of dependence. It was discovered and brought to market in 1976 by Imperial Chemical Industries and was withdrawn from the market in the early 2000s for business reasons.
Tianeptine, sold under the brand names Stablon and Coaxil among others, is an atypical antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irritable bowel syndrome.
Long-term or "continuous" video-electroencephalography (EEG) monitoring is a diagnostic technique commonly used in patients with epilepsy. It involves the long-term hospitalization of the patient, typically for days or weeks, during which brain waves are recorded via EEG and physical actions are continuously monitored by video. In epileptic patients, this technique is typically used to capture brain activity during seizures. The information gathered can be used for initial prognosis or long-term care management.
Neuropsychopharmacology, an interdisciplinary science related to psychopharmacology and fundamental neuroscience, is the study of the neural mechanisms that drugs act upon to influence behavior. It entails research of mechanisms of neuropathology, pharmacodynamics, psychiatric illness, and states of consciousness. These studies are instigated at the detailed level involving neurotransmission/receptor activity, bio-chemical processes, and neural circuitry. Neuropsychopharmacology supersedes psychopharmacology in the areas of "how" and "why", and additionally addresses other issues of brain function. Accordingly, the clinical aspect of the field includes psychiatric (psychoactive) as well as neurologic (non-psychoactive) pharmacology-based treatments. Developments in neuropsychopharmacology may directly impact the studies of anxiety disorders, affective disorders, psychotic disorders, degenerative disorders, eating behavior, and sleep behavior.
Theta waves generate the theta rhythm, a neural oscillatory pattern that can be seen on an electroencephalogram (EEG), recorded either from inside the brain or from electrodes attached to the scalp. Two types of theta rhythm have been described. The hippocampal theta rhythm is a strong oscillation that can be observed in the hippocampus and other brain structures in numerous species of mammals including rodents, rabbits, dogs, cats, bats, and marsupials. "Cortical theta rhythms" are low-frequency components of scalp EEG, usually recorded from humans. Theta rhythms can be quantified using quantitative electroencephalography (qEEG) using freely available toolboxes, such as, EEGLAB or the Neurophysiological Biomarker Toolbox (NBT).
Mental disorders are classified as a psychological condition marked primarily by sufficient disorganization of personality, mind, and emotions to seriously impair the normal psychological and often social functioning of the individual. Individuals diagnosed with certain mental disorders can be unable to function normally in society. Mental disorders occasionally consist of a combination of affective, behavioral, cognitive and perceptual components. The acknowledgement and understanding of mental health conditions has changed over time and across cultures. There are still variations in the definition, classification, and treatment of mental disorders.
Protriptyline, sold under the brand name Vivactil among others, is a tricyclic antidepressant (TCA), specifically a secondary amine, indicated for the treatment of depression and attention-deficit hyperactivity disorder (ADHD). Uniquely among most of the TCAs, protriptyline tends to be energizing instead of sedating, and is sometimes used for narcolepsy to achieve a wakefulness-promoting effect.
A generalized tonic–clonic seizure, commonly known as a grand mal seizure or GTCS, is a type of generalized seizure that produces bilateral, convulsive tonic and clonic muscle contractions. Tonic–clonic seizures are the seizure type most commonly associated with epilepsy and seizures in general and the most common seizure associated with metabolic imbalances. It is a misconception that they are the sole type of seizure, as they are the main seizure type in approximately 10% of those with epilepsy.
Max Fink is an American neurologist and psychiatrist best known for his work on ECT. His early work also included studies on the effect of psychoactive drugs on brain electrical activity; more recently he has written about the syndromes of catatonia and melancholia.
Spike-and-wave is a pattern of the electroencephalogram (EEG) typically observed during epileptic seizures. A spike-and-wave discharge is a regular, symmetrical, generalized EEG pattern seen particularly during absence epilepsy, also known as ‘petit mal’ epilepsy. The basic mechanisms underlying these patterns are complex and involve part of the cerebral cortex, the thalamocortical network, and intrinsic neuronal mechanisms. The first spike-and-wave pattern was recorded in the early twentieth century by Hans Berger. Many aspects of the pattern are still being researched and discovered, and still many aspects are uncertain. The spike-and-wave pattern is most commonly researched in absence epilepsy, but is common in several epilepsies such as Lennox-Gastaut syndrome (LGS) and Ohtahara syndrome. Antiepileptic drugs (AEDs) are commonly prescribed to treat epileptic seizures, and new ones are being discovered with fewer adverse effects. Today, most of the research is focused on the origin of the generalized bilateral spike-and-wave discharge. One proposal suggests that a thalamocortical (TC) loop is involved in the initiation spike-and-wave oscillations. Although there are several theories, the use of animal models has provided new insight on spike-and-wave discharge in humans.
Electroencephalography (EEG) is an electrophysiological monitoring method to record electrical activity of the brain. It is typically noninvasive, with the electrodes placed along the scalp, although invasive electrodes are sometimes used, as in electrocorticography. EEG measures voltage fluctuations resulting from ionic current within the neurons of the brain. Clinically, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time, as recorded from multiple electrodes placed on the scalp. Diagnostic applications generally focus either on event-related potentials or on the spectral content of EEG. The former investigates potential fluctuations time locked to an event, such as 'stimulus onset' or 'button press'. The latter analyses the type of neural oscillations that can be observed in EEG signals in the frequency domain.
Audio-visual entrainment (AVE), a subset of brainwave entrainment, uses flashes of lights and pulses of tones to guide the brain into various states of brainwave activity. AVE devices are often termed light and sound machines or mind machines. Altering brainwave activity is believed to aid in the treatment of psychological and physiological disorders.
Traxoprodil is a drug developed by Pfizer which acts as an NMDA antagonist, selective for the NR2B subunit. It has neuroprotective, analgesic, and anti-Parkinsonian effects in animal studies. Traxoprodil has been researched in humans as a potential treatment to lessen the damage to the brain after stroke, but results from clinical trials showed only modest benefit. The drug was found to cause EKG abnormalities and its clinical development was stopped. More recent animal studies have suggested traxoprodil may exhibit rapid-acting antidepressant effects similar to those of ketamine, although there is some evidence for similar psychoactive side effects and abuse potential at higher doses, which might limit clinical acceptance of traxoprodil for this application.
References
History.
Fink M. Pharmacoelectroenephalography: A note on its history. Neuropsychobiology 1984; 12:173-178
Fink M. A clinician-researcher and ECDEU: 1959-1980. In: T. Ban, D. Healy, E. Shorter (Eds.): The Triumph of Psychopharmacology and the Story of the CINP. Budapest, Animula, 82-96, 2000.
Fink M. Pharmaco-Electroencephalography: A Selective History of the Study of Brain Responses to Psychoactive Drugs. In: T. Ban, E. Shorter, D. Healy (Eds.): History of CINP, IV: 661-672, 2004.
Galderisi S, Sannita WG. Pharmaco-EEG: A history of progress and missed opportunity. Clinical EEG and Neuroscience 37:61-65, 2006;
Fink M. Remembering the lost science of pharmaco-EEG. Acta psychiatr Scand., 121:161-173. 2010
Methodology
Brazier MAB (Ed): Computer Techniques in EEG Analysis. EEG Journal, Supplement 20, 1-98, 1961.
Stille G, Herrmann W, Bente D, Fink M, Itil T, Koella WP, Kubicki S, Künkel H, Kugler J, Matejcek M, Petsche H. Guidelines for pharmaco-EEG studies in man. Pharmacopsychiatry 15:107-108;1982
Herrmann WM, Abt K, Coppola R, et al. International Pharmaco-EEG Group (IPEG). Recommendations for EEG and evoked potential mapping. Neuropsychobiology 22:170-176. 1989
Association or dissociation?
Wikler A. Pharmacologic dissociation of behavior and EEG 'sleep patterns' in dogs: Morphine, n-allynormorphine and atropine. Proc Soc exp Biol 79:261-264, 1952;
Wikler A. Clinical and electroencephalographic studies on the effect of mescaline, n-allyInormorphine and morphine in man. J nerv ment Dis 120:157-175, 1954.
Fink M. EEG classification of psychoactive compounds in man: Review and theory of behavioral association. In: Efron D, Cole JO, Levine J, Wittenborn JR. (Eds): Psychopharmacology: A Review of Progress 1957-1967 U.S.G.P.O., Washington, D.C., 497-507, 1968;
Fink M., Itil T. Neurophysiology of the phantastica: EEG and behavioral relations in man. In: Efron D, Cole JO, Levine J, Wittenborn JR. (Eds): Psychopharmacology: A Review of Progress 1957-1967. U.S.G.P.O., Washington, D.C., 1231-1239, 1968;
Fink M. Itil T. EEG and human psychopharmacology: IV: Clinical antidepressants. In: Efron D, Cole JO, Levine J, Wittenborn JR. (Eds): Psychopharmacology: A Review of Progress 1957-1967. U.S.G.P.O., Washington, D.C., 671-682, 1968;
Fink M. EEG and human psychopharmacology. Annu Rev Pharmacol 9:241-258, 1969;
Bradley P and Fink M. (Eds): Anticholinergic Drugs and Brain Functions in Animals and Man. Prog Brain Res 28, 184 pp., 1968.
Fink M. EEG and behavior: Association or dissociation in man? Integrative Psychiatry 9:108-123, 1993.
Examples of human studies.
Fink M, Kahn RL. Relation of EEG delta activity to behavioral response in electroshock: Quantitative serial studies. Arch Neurol & Psychiatry 78:516-525,1957
Fink M. Electroencephalographic and behavioral effects of Tofranil. Canad Psychiat Assoc J, 4 (suppl) 166-71, 1959.
Itil TM, Polvan N, Hsu W. Clinical and EEG effects of GB-94, a tetracyclic antidepressant: EEG model in the discovery of a new psychotropic drug. Curr Ther Res 14:395-413, 1972.
Volavka J, Levine R, Feldstein S, Fink M. Short-term effects of heroin in man. Arch Gen Psychiatry 30:677-684,1974.
Itil TM, Cora R, Akpinar S, Herrmann WH, Patterson CJ. "Psychotropic" action of sex hormones: Computerized EEG in establishing the immediate CNS effects of steroid hormones. Curr Therapeutic Res 16:1147-1170, 1974.
Fink M, Kety S, McGaugh J (Eds.): Psychobiology of Convulsive Therapy. Washington DC: VH Winston & Sons, 1974.
Volavka J, Fink M, Panayiotopoulos CP. Acute EEG effects of cannabis preparations in long-term users. In: C. Stefanis, R. Dornbush, M Fink (Eds): Hashish- A Study of Long-Term Use. NY: Raven Press, 1977.
American Psychiatric Association Electroconvulsive therapy. Task Force Report #14. Washington, DC: American Psychiatric Association. (1978). (200 pp.).
Fink M, Irwin P, Sannita W, Papakostas Y, Green MA. Phenytoin: EEG effects and plasma levels in volunteers. Therap Drug Monitoring 1: 93-104, 1979.
Fink M and Irwin P. EEG and behavioral profile of flutroline (CP-36,584), a novel antipsychotic drug. Psychopharmacology 72: 67-71, 1981.
Fink M and Irwin P. Pharmaco-EEG study of 6-azamianserin (ORG-3770): Dissociation of EEG and pharmacologic predictors of antidepressant activity. Psychopharmacology 78: 44-48, 1982.
Fink M, Irwin P. CNS effects of acetylsalicylic acid (Aspirin). Clin Pharm Therap 32:362-365, 1982.
Additional notes.
Meetings of interested scientists began at the World Congress of Psychiatry meeting in Montreal in 1961 and the CINP meeting in Washington D.C. in 1966. Thereafter, biennial meetings of the IPEG (International Pharmaco-EEG Group) were scheduled at different cities, mainly in Europe, <http://www.ipeg-society.org/>. The proceedings were published in volumes with different editors cited in Fink (1984).
The ACNP recorded interviews with leading scientists. Transcripts are published in Ban T, Fink M. (Eds.): Oral History of Neuropsychopharmacology: The First Fifty Years:Neurophysiology. Brentwood TN: ACNP. Volume 2: 319 pp.
Fink M interviewed by Cole JO, in An Oral History of Neuropsychopharmacology - The First Fifty Years: Peer Interviews (Thomas A. Ban, editor), Volume 2- "Neurophysiology" (Max Fink, volume editor). Brentwood: American College of Neuropsychopharmacology; 2011. p.7 - 20.
Fink M interviewed by Healy D, in An Oral History of Neuropsychopharmacology - The First Fifty Years: Peer Interviews (Thomas A. Ban, editor), Volume 9- "Update" (Barry Blackwell, volume editor). Brentwood: American College of Neuropsychopharmacology; 2011. p.73 - 104.
SBU Library. Max Fink's archives from the 1950s to the present are at the Special Collections of the Frank Melville Memorial Library of Stony Brook University, Stony Brook, New York .
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
